language
Language
Englishchevron_right
attach_money
Currency
$USDchevron_right
dark_mode
Dark Mode
policy
Privacy Policy
gavel
Terms of Service
AMPHAMPH

$20.23

-6.26
arrow_drop_down23.63%
Market closed·update27 Feb 2026 21:00

$20.53

+0.30
arrow_drop_up1.48%
Post-market·update28 Feb 2026 00:56
Day's Range
19.83-23.265
52-week Range
19.83-31.26

Chart

Loading chart...

Performance

Key Stats

Next Earnings Date2026-02-26
Next Earnings TimeAfter Market Close
Volume1.48M
Average Volume 30d386.88K

AI AMPH Summary

Powered by LiveAI
💰
25.5
Valuation (P/E Ratio)
Reasonable for growth sector
📈
0.152
EPS Growth (YoY)
Strong earnings growth
Show More 🔒

AI Scoreboard

Powered by LiveAI
🔒

Overall Analysis

Buy
75

Amphastar Pharmaceuticals demonstrates strong fundamental performance, particularly in profitability and revenue growth. While its valuation is reasonable, technical indicators suggest a neutral to slightly cautious short-term outlook. The company operates in a resilient sector with ongoing demand for its products.

Neutral

Thematic

65

The pharmaceutical and biotechnology sector is generally stable, with consistent demand for essential medicines. Amphastar's focus on generics and specialized injectables positions it well within this stable landscape, though it may not be at the forefront of highly disruptive thematic trends like AI in drug discovery.

Strong

Fundamental

85

Amphastar Pharmaceuticals exhibits robust financial health with strong profitability, consistent revenue growth, and a manageable debt level. Its solid balance sheet and positive free cash flow generation are key strengths.

Neutral

Technical

55

Amphastar's technicals show mixed signals. While it's trading above key moving averages, suggesting some upward momentum, several indicators are neutral or lean towards sell, hinting at potential short-term choppiness or consolidation.

FactorScore
Healthcare Demand75
Biotechnology Innovation50
Generic Drug Market70
Regulatory Landscape60
FactorScore
Valuation90
Profitability95
Growth80
Balance Sheet Health75
Cash Flow85
FactorScore
Trend Analysis70
Momentum50
Volume Confirmation60
Support & Resistance40

AI Investing Checklist

Powered by LiveAI
thumb_up

Bullish Points (7)

Earnings Performance chevron_right

Positive Earnings Surprises

The company has exceeded earnings per share (EPS) estimates in 7 out of the last 12 reported quarters, with a notable surprise of 21.55% in Q3 2024.

Financial Health & Liquidity chevron_right

Strong Free Cash Flow Generation

Free cash flow has consistently been positive, reaching $172.345 million in 2024, indicating efficient operations and strong cash generation capabilities.

Show More 🔒
thumb_down

Bearish Points (7)

Performance chevron_right

Significant Short-Term Underperformance

The stock has experienced substantial declines over the past 1M (-11.58%) and 6M (-39.73%) periods, indicating recent negative investor sentiment.

Valuation chevron_right

High Price-to-Sales Ratio

The TTM Price-to-Sales (PS) ratio is 1.9, which, while not extremely high in all industries, could be a concern if revenue growth is not robust.

Show More 🔒

Calendar

August 2025

7

Next Earnings Date

EPS Est.
Revenue Est.

H: $0.82

A: $0.74

L: $0.60

H: 182.00M

A: 173.41M

L: 161.00M

Profile

Employees (FY)2.03K
ISINUS03209R1032
FIGI-

Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency. The company also provides Amphadase, a bovine-sourced hyaluronidase injection; Epinephrine injection for allergic reactions; Lidocaine jelly, an anesthetic product for urological procedures; Lidocaine topical solution for various procedures; Phytonadione injection, a vitamin K1 injection for newborn babies; emergency syringe products; morphine injection for use with patient-controlled analgesia pumps; and Lorazepam injection for surgery and medical procedures. In addition, it offers Neostigmine methylsulfate injection to treat myasthenia gravis and to reverse the effects of muscle relaxants; Isoproterenol hydrochloride injection for mild or transient episodes of heart block; Ganirelix Acetate injection for the inhibition of premature luteinizing hormone surges; Vasopressin to increase blood pressure; and Regadenoson, a stress agent for radionuclide myocardial perfusion imaging, as well as Albuterol Sulfate inhalation aerosol. Further, the company distributes recombinant human insulin APIs and porcine insulin API. Additionally, it develops generic product candidates, such as injectable, inhalation, and analytical technologies; biosimial product candidates; and intranasal epinephrine for the treatment of allergic reactions. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.

Seasonals

2025
2024
2023
2022
2021

Price Target

32.40 USD

The 39 analysts offering 1 year price forecasts for AMPH have a max estimate of 38.00 and a min estimate of 29.00.

Debt Level and Coverage

Debt
Free cash flow
Cash & equivalents

Financial Position Analysis

Assets
Liabilities

Ownership

Free Float shares
36M (76.34%)
Closely held shares
11.2M (23.66%)
47.1M
Free Float shares
36M (76.34%)
Closely held shares
11.2M (23.66%)

Capital Structure

Market cap
1.06B
Debt
650.55M
Minority interest
0.00
Cash & equivalents
151.61M
Enterprise value
1.56B

Valuation - Summary

Market Cap
1.06B
Net income
104M(9.77%)
Revenue
548M(51.67%)
1.06B
Market Cap
1.06B
Net income
104M(9.77%)
Revenue
548M(51.67%)
Price to earning ratio (P/E)10.20x
Price to sales ratio (P/S)1.90x

Valuation - Ratios

P/E
P/S

Revenue to Profit Conversion

Revenue
731.97M
COGS
358.11M
Gross Profit
373.86M
OpEx
168.44M
Operating Income
205.42M
Other & Taxes
45.9M
Net Income
159.52M

Balance Sheet

Total assets
Total liabilities
Liabilities to assets %

Income Statement

Revenue
Net Income
Net Margin

Cash Flow

Operating Cash Flow
Investing Cash Flow
Financing Cash Flow
Show More 🔒